메뉴 건너뛰기




Volumn 103, Issue 8, 2010, Pages 1154-1162

A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer

Author keywords

C reactive protein; interleukin 6; metastatic renal cell cancer; siltuximab

Indexed keywords

CNTO 328; INTERLEUKIN 6 ANTIBODY; SILTUXIMAB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; INTERLEUKIN 6; MONOCLONAL ANTIBODY;

EID: 77957995258     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605872     Document Type: Article
Times cited : (163)

References (32)
  • 1
    • 14644435101 scopus 로고    scopus 로고
    • Interleukin-6 and C-reactive protein in metastatic renal cell carcinoma
    • author reply 1044-1045
    • Altundag O, Altundag K, Gunduz E (2005) Interleukin-6 and C-reactive protein in metastatic renal cell carcinoma. J Clin Oncol 23: 1044; author reply 1044-1045
    • (2005) J Clin Oncol , vol.23 , pp. 1044
    • Altundag, O.1    Altundag, K.2    Gunduz, E.3
  • 2
    • 0037428774 scopus 로고    scopus 로고
    • Metastatic renal carcinoma comprehensive prognostic system
    • Atzpodien J, Royston P, Wandert T, Reitz M (2003) Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer 88: 348-353
    • (2003) Br J Cancer , vol.88 , pp. 348-353
    • Atzpodien, J.1    Royston, P.2    Wandert, T.3    Reitz, M.4
  • 5
    • 0034824273 scopus 로고    scopus 로고
    • Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy
    • Capuron L, Ravaud A, Gualde N, Bosmans E, Dantzer R, Maes M, Neveu PJ (2001) Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy. Psychoneuroendocrinology 26: 797-808
    • (2001) Psychoneuroendocrinology , vol.26 , pp. 797-808
    • Capuron, L.1    Ravaud, A.2    Gualde, N.3    Bosmans, E.4    Dantzer, R.5    Maes, M.6    Neveu, P.J.7
  • 7
    • 0037398224 scopus 로고    scopus 로고
    • Serum C-reactive protein correlates with survival in colorectal cancer patients but is not an independent prognostic indicator
    • Chung YC, Chang YF (2003) Serum C-reactive protein correlates with survival in colorectal cancer patients but is not an independent prognostic indicator. Eur J Gastroenterol Hepatol 15: 369-373
    • (2003) Eur J Gastroenterol Hepatol , vol.15 , pp. 369-373
    • Chung, Y.C.1    Chang, Y.F.2
  • 11
    • 0036269257 scopus 로고    scopus 로고
    • Therapeutic options in the management of renal cell carcinoma
    • Glaspy JA (2002) Therapeutic options in the management of renal cell carcinoma. Semin Oncol 29: 41-46
    • (2002) Semin Oncol , vol.29 , pp. 41-46
    • Glaspy, J.A.1
  • 13
    • 34548804499 scopus 로고    scopus 로고
    • C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: A European study of 313 patients
    • Karakiewicz PI, Hutterer GC, Trinh QD, Jeldres C, Perrotte P, Gallina A, Tostain J, Patard JJ (2007) C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: a European study of 313 patients. Cancer 110: 1241-1247
    • (2007) Cancer , vol.110 , pp. 1241-1247
    • Karakiewicz, P.I.1    Hutterer, G.C.2    Trinh, Q.D.3    Jeldres, C.4    Perrotte, P.5    Gallina, A.6    Tostain, J.7    Patard, J.J.8
  • 16
    • 0031415831 scopus 로고    scopus 로고
    • Serum interleukin-6 in relation to acute-phase reactants and survival in patients with renal cell carcinoma
    • Ljungberg B, Grankvist K, Rasmuson T (1997) Serum interleukin-6 in relation to acute-phase reactants and survival in patients with renal cell carcinoma. Eur J Cancer 33: 1794-1798
    • (1997) Eur J Cancer , vol.33 , pp. 1794-1798
    • Ljungberg, B.1    Grankvist, K.2    Rasmuson, T.3
  • 17
    • 0028885888 scopus 로고
    • Measurement of whole body interleukin-6 (IL-6) production: Prediction of the efficacy of anti-IL-6 treatments
    • Lu ZY, Brailly H, Wijdenes J, Bataille R, Rossi JF, Klein B (1995) Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments. Blood 86: 3123-3131
    • (1995) Blood , vol.86 , pp. 3123-3131
    • Lu, Z.Y.1    Brailly, H.2    Wijdenes, J.3    Bataille, R.4    Rossi, J.F.5    Klein, B.6
  • 18
    • 0036583165 scopus 로고    scopus 로고
    • The role of C-reactive protein as a prognostic indicator in advanced cancer
    • Mahmoud FA, Rivera NI (2002) The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep 4: 250-255
    • (2002) Curr Oncol Rep , vol.4 , pp. 250-255
    • Mahmoud, F.A.1    Rivera, N.I.2
  • 19
    • 1442290393 scopus 로고    scopus 로고
    • Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma
    • Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, Mazumdar M (2004) Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22: 454-463
    • (2004) J Clin Oncol , vol.22 , pp. 454-463
    • Motzer, R.J.1    Bacik, J.2    Schwartz, L.H.3    Reuter, V.4    Russo, P.5    Marion, S.6    Mazumdar, M.7
  • 20
    • 33846821872 scopus 로고    scopus 로고
    • Targeted therapy for metastatic renal cell carcinoma
    • Motzer RJ, Bukowski RM (2006) Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 24: 5601-5608
    • (2006) J Clin Oncol , vol.24 , pp. 5601-5608
    • Motzer, R.J.1    Bukowski, R.M.2
  • 22
    • 2942756034 scopus 로고    scopus 로고
    • Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: Prognostic value of interleukin-6-from the Groupe Francais d'Immunotherapie
    • Negrier S, Perol D, Menetrier-Caux C, Escudier B, Pallardy M, Ravaud A, Douillard JY, Chevreau C, Lasset C, Blay JY (2004) Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6-from the Groupe Francais d'Immunotherapie. J Clin Oncol 22: 2371-2378
    • (2004) J Clin Oncol , vol.22 , pp. 2371-2378
    • Negrier, S.1    Perol, D.2    Menetrier-Caux, C.3    Escudier, B.4    Pallardy, M.5    Ravaud, A.6    Douillard, J.Y.7    Chevreau, C.8    Lasset, C.9    Blay, J.Y.10
  • 23
    • 0028952405 scopus 로고
    • Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma
    • Finnish Leukemia Group
    • Pelliniemi TT, Irjala K, Mattila K, Pulkki K, Rajamaki A, Tienhaara A, Laakso M, Lahtinen R (1995) Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukemia Group. Blood 85: 765-771
    • (1995) Blood , vol.85 , pp. 765-771
    • Pelliniemi, T.T.1    Irjala, K.2    Mattila, K.3    Pulkki, K.4    Rajamaki, A.5    Tienhaara, A.6    Laakso, M.7    Lahtinen, R.8
  • 24
    • 77649172209 scopus 로고    scopus 로고
    • Pharmaco-kinetic and pharmacodynamic modeling of an anti-interleukin-6 chimeric monoclonal antibody (siltuximab) in patients with metastatic renal cell carcinoma
    • Puchalski T, Prabhakar U, Jiao T, Berns B, Davis HM (2010) Pharmaco-kinetic and pharmacodynamic modeling of an anti-interleukin-6 chimeric monoclonal antibody (siltuximab) in patients with metastatic renal cell carcinoma. Clin Cancer Res 16: 1652-1661
    • (2010) Clin Cancer Res , vol.16 , pp. 1652-1661
    • Puchalski, T.1    Prabhakar, U.2    Jiao, T.3    Berns, B.4    Davis, H.M.5
  • 26
    • 0344665774 scopus 로고    scopus 로고
    • Impact of tumor-associated symptoms on the prognosis of patients with renal cell carcinoma: A single-center experience of 683 patients
    • Schips L, Lipsky K, Zigeuner R, Salfellner M, Winkler S, Langner C, Rehak P, Pummer K, Hubmer G (2003) Impact of tumor-associated symptoms on the prognosis of patients with renal cell carcinoma: a single-center experience of 683 patients. Urology 62: 1024-1028
    • (2003) Urology , vol.62 , pp. 1024-1028
    • Schips, L.1    Lipsky, K.2    Zigeuner, R.3    Salfellner, M.4    Winkler, S.5    Langner, C.6    Rehak, P.7    Pummer, K.8    Hubmer, G.9
  • 28
    • 0029780037 scopus 로고    scopus 로고
    • Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop
    • van Zaanen HC, Koopmans RP, Aarden LA, Rensink HJ, Stouthard JM, Warnaar SO, Lokhorst HM, van Oers MH (1996) Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop. J Clin Invest 98: 1441-1448
    • (1996) J Clin Invest , vol.98 , pp. 1441-1448
    • Van Zaanen, H.C.1    Koopmans, R.P.2    Aarden, L.A.3    Rensink, H.J.4    Stouthard, J.M.5    Warnaar, S.O.6    Lokhorst, H.M.7    Van Oers, M.H.8
  • 30
    • 0028896292 scopus 로고
    • Hypercalcemia and cosecretion of interleukin-6 and parathyroid hormone related peptide by a human renal cell carcinoma implanted into nude mice
    • Weissglas M, Schamhart D, Lowik C, Papapoulos S, Vos P, Kurth KH (1995) Hypercalcemia and cosecretion of interleukin-6 and parathyroid hormone related peptide by a human renal cell carcinoma implanted into nude mice. J Urol 153: 854-857
    • (1995) J Urol , vol.153 , pp. 854-857
    • Weissglas, M.1    Schamhart, D.2    Lowik, C.3    Papapoulos, S.4    Vos, P.5    Kurth, K.H.6
  • 31
    • 34548208088 scopus 로고    scopus 로고
    • Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis
    • Yang J, Wezeman M, Zhang X, Lin P, Wang M, Qian J, Wan B, Kwak LW, Yu L, Yi Q (2007) Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis. Cancer Cell 12: 252-265
    • (2007) Cancer Cell , vol.12 , pp. 252-265
    • Yang, J.1    Wezeman, M.2    Zhang, X.3    Lin, P.4    Wang, M.5    Qian, J.6    Wan, B.7    Kwak, L.W.8    Yu, L.9    Yi, Q.10
  • 32
    • 3843139682 scopus 로고    scopus 로고
    • CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice
    • Zaki MH, Nemeth JA, Trikha M (2004) CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice. Int J Cancer 111: 592-595
    • (2004) Int J Cancer , vol.111 , pp. 592-595
    • Zaki, M.H.1    Nemeth, J.A.2    Trikha, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.